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OBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural
effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a
recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim
of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model.
METHODS: New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of
2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and
creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGFb) parameters were measured in the pleural
fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro- (pleura) and
microscopic (pleura and retina) analyses were performed.
RESULTS: An early pleural inflammatory response with low systemic repercussion was observed without
corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with
greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were
observed in the retinal pigment epithelium of the rabbits.
CONCLUSION: Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model.
However, its efficacy, tolerance and safety in humans should be further evaluated.
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& INTRODUCTION
Despite the preferential use of long-term catheters to
control recurrent malignant pleural effusions, chemical
pleurodesis persists as an important therapeutic tool. The
ideal sclerosing agent should be inexpensive, widely
available and easily managed, in addition to low morbidity
and the absence of mortality. Although pleurodesis was first
performed at the beginning of the 20th century using silver
nitrate, talc progressively gained wide preference (1,2).
Nevertheless, despite impressive results, the heterogeneity
of talc particles has been implicated in causing undesirable
side effects, sometimes culminating in respiratory failure
and death (3,4).
These facts have stimulated clinical and experimental
studies to reevaluate the effectiveness and safety of previously
used sclerosing agents, such as iodopovidone, a topical
antiseptic that is recognized as a safe (minimal side effects)
and effective (.90%) (5), although visual loss has been
reported by Wagenfeld et al. (6). It should be highlighted that
the dose reported in this study was higher than the standard
dose that has been used in other clinical studies (7-9).
The purpose of this study was to evaluate pleurodesis
development in an animal model and to analyze the possible
systemic effects after intrapleurally injecting iodopovidone.
& MATERIALS AND METHODS
This project was developed at the Pleura Laboratory of the
Pulmonary Division of the Heart Institute (HC-FMUSP) after
approval by the Ethics Committee Board. New Zealand
rabbits (2.0-3.0 kg) were randomized and subdivided into
groups (five animals each) according to the time of euthanasia
(1, 3, 7, 14 or 28 days).
As previously described, the animals were submitted to
sedation and analgesia (35 mg/kg of ketamine hydrochloride
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[Cristalia, Brazil] and 5 mg/kg of xylazine hydrochloride
[Bayer, Brazil]) (10-12). Next, trichotomy of the right
hemithorax and antisepsis were performed; a 0.5 cm incision
(hemiclavicular line) was then made over the projection of
the sixth rib. A catheter (8 Fr) was then tunneled into the
subcutaneous tissue, and after exposing the parietal pleura, it
was inserted into the cavity and attached to the skin. Through
the catheter, 2 mL of iodopovidone (Rioquimica, Brazil) was
injected at 2%, 4% or 10% concentrations. The left hemithorax
(not injected) was used as a control.
Every 24 hours, the drain was aspirated, and the pleural
fluid was quantified and stored with concurrently collected
blood samples. The drain was removed after the seventh
day, when the fluid drainage was ,1 mL/day. At the
predetermined times, the animals were euthanized; the
thorax was removed en bloc, and the lungs were expanded
and maintained submersed (10% formalin) for 48 hours.
Next, the pleural cavity was exposed for macroscopic
evaluation (10-12). For histological analysis of the retina,
the rabbit eyes were enucleated and fixed (10% formalin) for
slide preparation and Hematoxylin & Eosin (H&E) staining.
Lactic dehydrogenase (kinetic UV method), total protein
(Biuret method), and the Interleukin-8 (IL-8), VEGF and TGF-
b1 (ELISA method) cytokines were quantified in the blood
and pleural fluid. Thyroid hormone levels (triiodothyronine
and free thyroxine) in the blood was detected using
chemiluminescence (ImmuLITE 2000, Siemens, Erlangen,
Germany), and the levels of renal function markers (urea
and creatinine) were determined with the kinetic UV method.
Baseline serum levels were obtained from the rabbits prior
to iodopovidone treatment and were used as the control.
Macroscopic and microscopic evaluations were performed
according to previously described methodology (10-12). A
consensus grading of the macroscopic adhesions was reached
by two investigators (LRT and JP) who were blinded with
respect to the treatment group using the semi-quantitative
scheme: (0) normal pleural space, (1) 1-3 small adherences, (2)
over 3 adherences in which the lung can easily be separated
from the thorax, (3) generalized adhesions (containing areas
where the lung could only be separated from the thoracic
wall with difficulty) and (4) complete obliteration of the
pleural space by adhesions. The pleura visceral fragments
were processed, stained (hematoxylin–eosin), and evaluated
for the presence of thickening using grades from 0-4:
0 = none, 1 = equivocal, 2 = mild, 3 = moderate and 4 = marked
changes. The microscopic analysis was performed by two
examiners (LA and MMPA) who were blinded to the
treatment. Retina fragments were also H&E stained and
analyzed with light microscopy by two independent inves-
tigators (LRT and FMD).
Statistical Analysis
The results are presented as median and interquartile
range (25%-75%). Comparisons among the three groups
were performed using non-parametric tests (the Mann-
Whitney rank sum test or Kruskal-Wallis analysis of
variance on ranks). A value of p,0.05 was considered
significant. The SigmaStat 3.1 (Systat, CA, USA) program
was used for the analyses.
& RESULTS
Figure 1 shows the characteristics of the inflammatory
response after the iodopovidone instillation. Progressive
pleural exudation was observed, with maximum fluid
drainage at seven days (2%, 23 mL [11-46 mL], p= 0.035;
4%, 34 mL [32-44 mL], p= 0.003 and 10%, 43 mL [29-49 mL],
p= 0.004). On the first (p,0.001) and third (p= 0.045) days
following the pleural injection, the fluid produced with 4%
and 10% iodine was superior to that produced with 2%
iodine. After the seventh day, the pleural fluid markedly
diminished in the majority of the animals, regardless of the
concentration; this result precluded the statistical analyses
in the groups. There were no differences in the protein
levels among the groups. Regardless of the injected
concentration, a marked elevation of lactic dehydrogenase
was evident only in the pleural fluid. Twenty-four hours
following the instillation, the levels were significantly
greater than those obtained after three days (2%, p,0.001;
4%, p= 0.003 and 10%, p= 0.002) or seven days (2%, p,0.001;
4%, p= 0.003 and 10%, p= 0.002).
Cytokine behavior is shown in Table 1. When the cytokine
levels in the pleural fluid and blood were compared on the
first day after injection, the IL-8 pleural was greater (2%,
p= 0.003; 4%, p= 0.015 and 10%, p,0.001). After this initial
increment, the pleural levels decreased beginning with the
third day and stabilized until the seventh day. At this time,
the IL-8 values were lower than those obtained in the blood
(4%, p,0.001 and 10%, p= 0.049). In all of the evaluated
periods, the serum levels were significantly greater than the
baseline level of 26 pg/mL (16-55).
In relation to VEGF (Table 1), the pleural values exceeded
the serum value of 31 (31-34) during the entire study period.
This cytokine was differentially expressed compared to IL-8,
with the maximum expression reached on day seven (2%,
p= 0.017; 4%, p= 0.003 and 10%, p= 0.004).
The pleural levels of TGF-b1 were significantly greater
than those obtained in the serum at 4% or 10% concentra-
tions on the third (4%, p= 0.022 and 10%, p,0.001) and
seventh days (4%, p= 0.041 and 10%, p,0.001). The temporal
analysis of the pleural fluid revealed stable values for the
2% concentration. At higher concentrations, we observed a
progressive increase of the fluid levels (p,0.001). The serum
values were also significantly greater than the baseline level
of 286 (244-313) in all of the evaluated periods (Table 1).
Analysis of thyroid hormones and renal function markers
(Figure 2) showed no significant differences among the
groups during the study period. Furthermore, the results
did not differ from the baseline values.
Analysis of macroscopic pleural adhesions demonstrated
a progressive increase over time and was more pronounced
in the animals injected with 4% or 10% iodine. Analogous
behavior was observed for visceral pleural thickening,
which was more pronounced at increased concentrations
of the sclerosing agent (Figure 3). Finally, the morphological
analysis of the retina showed no changes related to time or
iodine concentration. We did not observe any edemas or
alterations in retinal pigment epithelium (atrophy or
hypertrophy) or in photoreceptors. Cells from the inter-
mediate and internal retina were also within the normal
limits. No macro or microscopic changes were observed in
the left hemithorax (not injected, used as control).
& DISCUSSION
This study shows that the intrapleural injection of
iodopovidone causes an early pleural inflammatory
response with low systemic repercussion and no detectable
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Table 1 - The median and interquartile (25%-75%) f cytokine levels in the pleural fluid and blood during the acute
phase of iodopovidone intrapleural injection (1, 3 and 7 days), p,0.05 (*vs. day 1; # vs. day3; 1 vs. 2%).
Pleural Fluid Blood
2% 4% 10% p 2% 4% 10% p
IL-8 (pg/mL)
Basal 26 (16-55)
Day 1 2866 (2779-3459) 3961 (2044-4273) 4253 (3292-4443) 0.587 1362 (1083-1703) 1344 (1022-1531) 1664 (1557-2115) 0.121
Day 3 1083 (874-1107)* 921 (883-990)* 1189 (617-1551)* 0.733 875 (556-1684) 1395 (978-1695) 1981 (1796-2062) 0.101
Day 7 776 (535-953)* 747 (630-818)* 761 (662-1475)* 0.455 1121 (402-1973) 1270 (988-1343) 2321 (1173-2642) 0.289
p 0.007 0.003 ,0.001 0.849 0.913 0.802
VEGF (pg/mL)
Basal 31 (31-34)
Day 1 332 (233-583) 626 (527-763) 525 (470-889) 0.117 34 (30-37) 53 (39-56) 33 (22-54) 0.629
Day 3 602 (516-656) 462 (428-950) 1192 (793-1304) 0.069 45 (31-45) 49 (36-84) 85 (53-94) 0.328
Day 7 1483 (610-1545)* 1882 (1783-2959)* 2627 (1717-3420)* 0.064 31 (31-41)* 44 (37-45) 67 (49-110) 0.264
p 0.017 0.003 0.004 0.833 0.846 0.323
TGF-b1 (pg/mL)
Basal 286 (244-313)
Day 1 774 (701-872) 862 (601-965) 972 (764-1354) 0.217 444 (31-523) 382 (346-512) 875 (826-927) 0.009
Day 3 1164 (506-1443) 1315 (1234-1406)* 1726 (1624-2028)*1 0.031 736 (526-818) 580 (493-1021) 853 (674-902) 0.837
Day 7 989 (448-1585) 2128 (2104-2196)*#1 2439 (2064-2530)*#1 0.020 786 (633-959) 710 (636-841) 851 (533-1005) 0.912
p 0.794 ,0.001 ,0.001 0.067 0.027 0.066
Figure 1 - Results (median and interquartile range 25%-75%) of the pleural fluid volume and biochemical analyses during the acute
phase of the iodopovidone intrapleural injection (1, 3 and 7 days). (a) The volume of pleural fluid collected. (b) The total protein levels
in the pleural fluid. (c) Lactic dehydrogenase in the pleural fluid. (d) Lactic dehydrogenase levels in the blood.
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Figure 2 - The median and interquartile range (25%-75%) of renal function markers and thyroid hormones in the blood during the
study period (1-28 days). (a) The blood levels of urea, (b) creatinine, (c) Triiodothyronine and (d) free thyroxine.
Figure 3 - The median and interquartile range (25%-75%) of the evaluation of macroscopic pleural adhesions and microscopic
thickening after intrapleural iodopovidone during the study period (1 to –28 days). (a) Macroscopic adhesions evaluated using a 0-4
score. (b) Microscopic pleural thickness using a 0-4 score.
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side effects in our animal model. The higher iodine
concentrations (4% and 10%) resulted in an early increase
in pleural fluid production and more pronounced pleural
adhesions and thickening. Finally, iodopovidone, in the
studied concentrations, did not induce thyroid or renal
function changes or anatomical changes in the retinal
structure.
The mechanisms involved in pleural symphysis are not
completely known. Introducing a sclerosing agent into the
pleural space is known to damage the mesothelial cell
monolayer and trigger an inflammatory response that is
characterized by a neutrophilic exudate (13-15). The
subsequent events culminate with fibrotic adhesion devel-
opment between the pleural surfaces and the consequent
obliteration of the cavity. Among the factors involved in the
inflammatory response, we highlight mesothelial cell injury,
the collagen-secreting capacity of these cells and the
fibroblasts, the equilibrium between metalloproteinases
and plasminogen activators and the relationship between
cytokines and fibrinolysis (16).
Iodopovidone should be considered in addition to other
sclerosing agents used in clinical practice, as it is universally
found, easily manipulated and low cost (approximately $8
USD per 500 mL). Iodopovidone was introduced in the
1990s (17) and has an approximately 90% effectiveness (7-9).
Similar to other agents, the produced pleural symphysis is
most likely related to the injury of the mesothelial cells,
which are initially exteriorized by a progressive production
of pleural fluid with inflammatory characteristics.
During the first 24 hours after the iodine injection, an
expressive elevation of intrapleural lactic dehydrogenase,
which has a tendency to decrease over time, was identified;
the systemic repercussions were minimal. Guo et al. (18)
reported similar results after intrapleurally injecting iodine
at 2% or 4% concentrations, and Marchi et al. (19), who
induced experimental pleurodesis with talc or silver nitrate,
also obtained an early decrease in serum lactic dehydro-
genase, which reflected a local inflammatory response.
IL-8, an important mediator of the inflammatory process,
shows similar behavior to lactic dehydrogenase. Regardless
of the iodine concentration, pleural fluid IL-8 levels
increased early during the first 24 hours and progressively
decreased over time. In the serum, the IL-8 levels were
stable but greater than the basal values. VEGF carries out
multiple functions. In addition to participating in the initial
inflammatory process in which VEGF stimulates the
activation of mediators and facilitates the migration of
inflammatory cells, it has an important role in vascular
permeability, and, therefore, in pleural effusion production
(12). In this study, we observed a progressive and
accentuated elevation in pleural fluid, with minimal serum
increase. Note the correspondence between VEGF and the
intrapleural accumulation of fluid, which reinforces the role
of VEGF in pleural effusion formation.
Finally, TGF-b is also recognized for its multiple roles,
mainly in collagen deposition and fibrosis formation (16).
Although TGF-b expression largely paralleled VEGF expres-
sion in the pleural cavity, the TGF-b serum levels through-
out the study period were greater compared to the values
obtained before treatment. This behavior allowed us to
consider its participation in pleurodesis formation.
The result of this complex inflammatory process is pleural
symphysis. We have demonstrated that the intrapleural
injection of iodopovidone promotes, from the first 24 hours,
a framework of adhesions with temporal progression and
complete disappearance of the pleural cavity after 28 days.
In terms of the eventual side effects caused by iodopo-
vidone, we did not observe any severe damage.
Corroborating our findings, in a meta-analysis of observa-
tional studies, Agarwal et al. (5) demonstrated the efficacy
and safety of iodopovidone pleurodesis reporting an
absence of deaths. The most significant complication
reported was varying degrees of chest pain. Systemic
hypotension was reported in one study. Although this
review supports the safety and efficacy of iodopovidone as
an agent for chemical pleurodesis, no comments regarding
dosage or concentration have been mentioned. However, in
2000, Singalavanija et al. (20) described five patients who
presented higher serum creatinine levels and retinal
damage with visual impairment after mistakenly ingesting
potassium iodine orally at high concentrations. The authors
concluded that potassium iodine is a chemical substance
that in high doses can induce toxic effects on the retina,
thereby damaging the retinal epithelium and photorecep-
tors cells. Recently, Wagenfeld et al. (6) described visual loss
resulting from the breakdown of the diffusion barrier of the
retinal pigment epithelium in three patients who received a
10% iodopovidone solution during thoracoscopic surgery.
Note that the dose and the volume of iodopovidone used in
this procedure were much greater than that normally
recommended. Although our study has been conducted
on a small number of animals, we did not find changes or
damage in the retinal pigment epithelium of any rabbit,
even at the highest concentration (10%) of iodopovidone.
Another side effect that should be considered is a possible
thyroid blockage. Kovacikova et al. (21) reported that
iodopovidone, either in topical use or as contrast in image
procedures, may cause transient thyroid dysfunction,
mainly in children. High concentrations of exogenous
iodine are capable of diminishing thyroid hormone synth-
esis or induce thyrotoxicosis in susceptible individuals (22).
However, Yeginsu et al. (23) reported that the intrapleural
administration of 100 mL of 2% iodopovidone did not
affect thyroid hormone levels in humans. Although our
study was conducted in an animal model, we did not find
abnormal results in thyroid hormone levels, even in high
concentrations.
In conclusion, our findings suggest that iodopovidone is
an effective and safe sclerosing agent. Further studies in
humans should be conducted to determine the ideal dose
and concentration.
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